All News

Difficult to treat RA? #EULAR2022 1) Active/progressive disease, unable to taper steroids, radiographic progressive, decreased QoL 2) Failure of medications (2+ b/tsDMARD after csDMARD) 3) Physician/patient perception - Fatigue: not part of definition ~5-20% pts @Rheumnow https://t.co/i5sfwoF2Gs
Eric Dein ericdeinmd ( View Tweet)
When will this madness stop!? TNFi to treat OA (yet again). Adalimumab for "inflammatory" knee OA. And again it doesn't work. @RheumNow #EULAR2022 OP0229 https://t.co/htwyLTYwG4

Links:

Richard Conway RichardPAConway ( View Tweet)

#POS0787 #EULAR2022 More data to support the association of Anti-Ribosomal P ab with Depression + Cognitive Dysfunction using functional MRI in #lupus. To screen for neuropsychiatric in ab+ patients @RheumNow https://t.co/9JQDImrHAt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
✅ #EULAR2022 positive Phase 2 results for #deucravacitinib (TYK2 inhibitor) in systemic #Lupus with SRI(4) at 32W: - DEU 3mg BID: 58.2% (p=0.0006) - DEU 6mg BID: 49.5% (p=0.021) - DEU 12mg QD: higher (but NS) vs Placebo 34.4% + secondary endpoints. https://t.co/QCWqW97tre

Links:

Laurent ARNAUD Lupusreference ( View Tweet)

#Cytokine #StormHour 🌀🌪️ #EULAR2022 #Great session by Dr.Peter Nigrovic🔥 ❓Why sJIA/AOSD often accompanied by MAS❓⚡️ #Always wondered about this!🤔 ✅Multiple mechanisms at play ✅Whats New➡️IFN gamma switch ✅mTORC1 is the NEW PIECE in the puzzle of sJIA/AOSD/MAS!🧩🧩 https://t.co/xLzCABunMb
debaditya_roy debaditya_roy ( View Tweet)
#EULAR2022 quote of the day. I was going to go to the fatigue session @eular_org but I was too tired and burnt out! @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Subcutaneous #methotrexate in #rheumatoidarthritis is safer and better tolerated with better continuation rates than oral #MTX #eular2022 https://t.co/cjmKntsEMe
Volker Bahr VolkerBahr ( View Tweet)
#Lovely slide when deep into the maze of AOSD!🌎🔍❓ #EULAR2022 ⚡️Identify level of disease activity ⚡️Systemic/Articular? ⚡️Close monitoring ⚡️Identify non-responders early! ⏲️"DAVID" Project ongoing- validation of EULAR Disease Activity Score in AOSD! Exciting times ahead!🔥 https://t.co/fuPPj4lEhs
debaditya_roy debaditya_roy ( View Tweet)
I also wonder about the significance of Ro52. Some of the commonly observed features like gastrointestinal dysmotility are not captured. https://t.co/UPljYf65vH

Links:

Alberta Hoi alberta_hoi ( View Tweet)

#EULAR2022 How to Manage (HOT): Lupus Nephritis Voclosporin is the new CNI long term reno-ischemic effects need to be looked at https://t.co/8RqayemaRu
EnvisionRheumat ERheumat ( View Tweet)
#EULAR2022 WIN session Sarcoidosis – an update for rheumatologists Clinical Approach https://t.co/AYOEDsnDZ6
EnvisionRheumat ERheumat ( View Tweet)
#EULAR2022 COVID orals OP0172 Swedish COVID19-Reuma registry with n=414 ARD + 61 controls RTX n=145, ABA n=21 In MVA, use of RTX, ABA were a/w lower Ab response. We've known this about RTX; growing data for ABA as well? https://t.co/Es9bA54m8E
Rheum Cat rheum_cat ( View Tweet)
Excited to share our recent work "IPAF: What the Rheumatologist Needs to Know." @jeffsparks @UnaMakris @DrDavidKarp @UTSW_LungLadies @UTSWRheum https://t.co/O0BsrRyHx8 https://t.co/R3lQMGFgUb

Links:

Elena Joerns EJoerns ( View Tweet)
🔥Hot off the press🔥 🆕Our Comments on various GC protocols in @IJRheum The changing paradigm of glucocorticoid therapy in antineutrophil cytoplasmic antibody-associated vasculitis https://t.co/4BjfkvPVAY https://t.co/gMXg7qQJWY

Links:

Kunal Chandwar kunalchandwar ( View Tweet)
do we need another IL17a inhibitor? https://t.co/yf8cFNruzU
Peter Nash drpnash ( View Tweet)
"Implementation (of guidelines) is key but remains the weakest part of the process" Dr. @DanielAletaha #EULAR2022 @RheumNow https://t.co/9ULIAA7dvg
Dr. Rachel Tate uptoTate ( View Tweet)
Easy clinical tool for predicting lymphoma development at the time of #Sjogrens syndrome #EULAR2022 https://t.co/tQ6B0iVRnb
Christian Ammitzbøll RheumTweeter ( View Tweet)
Dr Buch. ORAL Surveillance. MACE, VTE, Malignancy all more common in those with high (>20%) baseline CV risk or history CAD. HRs 1-2 for most but for VTE and high baseline CV risk, HR 6-11! @RheumNow #EULAR2022 POS0237 https://t.co/9DI4KotyOp
Richard Conway RichardPAConway ( View Tweet)
Dr Elena Nikiphorou explaining how the Western diet can bring on and worsen inflammation joint disease symptoms. We should look to include more Omega 3 than Omega 6 in our diets #EULAR2022 PB https://t.co/nIKOSDPURU
ARD & RMD Open ARD_BMJ ( View Tweet)
A very comprehensive overview of progress in the understanding of #IIM pathogenetic mechanisms outlining the role of 👉 Type 1 INF pathway 👉 Vasculopathy 👉 NETs 👉 Mitochondrial Dysfunction #EULAR2022 Dr. Lisa Rider https://t.co/BXbXlYTHYM
Ashima Makol MD AshimaMakol ( View Tweet)
×